摘要
目的:观察Tju103和CTLA4-Ig各自对MHC半相合小鼠骨髓移植免疫耐受的诱导。方法:半相合供鼠T细胞与受鼠抗原、Tju103(或CTLA4-Ig)共育后与骨髓细胞混合移植,观测移植后受情况。结果:A.单纯照射组:全部小鼠于照射后11d内死于造血衰竭;B.白血病CTX治疗组:全部小鼠于接种白血病细胞后16~23d死于白血病;C.单纯移植组:全部小鼠于移植后21d内死于移植物抗宿主病(GVHD);D.CsA预防组:5只小鼠于移植后8~22d死亡,1只死于白血病,各有2只死于GVHD和感染,5只活过30d;E.Tju103处理组:4只小鼠于移植后9~26d死亡,2只死于GVHD,各有1只死于白血病和感染,6只活过30d;F.CTLA4-Ig处理组:2只小鼠于移植后17~26d死亡GVHD,8只活过30d。结论:Tju103和CT-LA4-Ig均明显延长生存期,降低GVHD发生和严重程度,CTLA4-Ig保留有抗感染和移植抗白血病(GVL)作用,而Tju103没有。
Objective: To observe the respective effects of Tju103 and CTLA4-Ig on tolerance, post haploidentical
mice bone marrow transplantation. Methods:In the presence of the recipient antigen, T cells from the haploidentical do-
nors were first cultured with Tju103 or CTLA4-Ig, then mixed with the bone marrow cells and transfused into the recipi-
ents. At last, they were observed on the effect on tolerance post transplantation. Results: A. The only irradiated group:
All the mice died of failure of hematopoiesis within 11 days post irradiation. B. The CTX-treated leukemia group: All the
mice died of leukemia within 16-23 days. C. The only transplanted group: All cases died of GVHD within 21 days post
transplantation. D. The CsA prophylaxis group: 5 mice died within 8-22 days after transplantation, of which one died of
leukemia, and two died of GVHD and infection respectively leaving 5 survived over 30 days post transplantation. E. The
Tju103 treated group: 4 mice died within 9-26 days post transplantation, of which one died of leukemia and infection re-
spectively, and two died of GVHD leaving 6 mice survived over 30 days post transplantation. F. The CTLA4-Ig treated
group: 2 mice died of GVHD within 17~26 days after transplantation leaving 8 survived over 30 days post transplantation.
Conclusions:Tju103 or CTLA4-Ig could alone improve survival time and reduce incidence and degree of GVHD respec-
tively. But CTLA4-Ig could preserve ability of GVL effect and anti-infection potential while Tju103 couldn't.
出处
《中国肿瘤生物治疗杂志》
CAS
CSCD
2003年第4期248-252,共5页
Chinese Journal of Cancer Biotherapy
基金
军队医学科学基金十五重点课题项目(01Z050)